| abstract |
Compounds of formula (1):wherein:G represents an optionally substituted phenyl or optionally substituted heterocycle, G1 and G2 being N or C,T1 represents -CH2-CH2-, -CH=CH- or =CH-CH2-, and T2 is a bond, or T1 represents -CH2- or =CH- and T2 is -CH2-, =CH-,R5 represents -(CH2)m-COOR6,R6 and R6' represent hydrogen, alkyl, optionally substituted aryl or optionally substituted arylalkyl,A represents -CO-, -CH2-, =CH- or -CH= and W represents -CH-, =C- or -C=, or A represents -CO- or -CH2- and W represents N,X represents -CO-X1-, -CO-NR6-X1-, -NR6-CO-X1-, -O-X1-, -SO2-NR6-X1- or -S(O)n-X1-,Y represents -Y1-, -Y2-Y1- or -Y1-Y2-Y1-, Y1 being an alkylene, alkenylene or alkynylene, and Y2 being an arylene, heteroarylene, cycloalkylene or heterocycloalkylene,Z represents -Z1-, -Z10-NR6-, and -Z10-NR6-CO-, Z1 being a heteroaryl, heterocycloalkyl, heteroarylalkyl, heterocycloalkylalkyl, fused arylheteroaryl, fused arylheterocycloalkyl, fused heteroarylheterocycloalkyl, fused heterocycloalkylheteroaryl or fused heteroarylheteroaryl, each of which is optionally substituted, or a group,Z2-NR6 or Z2-NR6-CO, Z2 being a group Z1, alkyl or heteroalkyl, andZ10 represents Z1 or an alkyl,its enantiomers, diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base,and medicinal products containing the same which are useful as vitronectin receptor antagonists. |